Nemes Rush Group LLC Has $5.48 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Nemes Rush Group LLC grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 4.0% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 25,933 shares of the medical research company’s stock after buying an additional 992 shares during the quarter. Nemes Rush Group LLC’s holdings in IQVIA were worth $5,483,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IQV. Canada Pension Plan Investment Board raised its position in IQVIA by 6.6% in the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after purchasing an additional 211,653 shares in the last quarter. Lazard Asset Management LLC boosted its stake in shares of IQVIA by 0.9% in the 1st quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock valued at $825,416,000 after purchasing an additional 30,014 shares in the last quarter. Farallon Capital Management LLC grew its holdings in shares of IQVIA by 3.1% in the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock worth $618,046,000 after purchasing an additional 86,870 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of IQVIA by 3.8% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock worth $634,927,000 after purchasing an additional 92,293 shares in the last quarter. Finally, Capital Research Global Investors lifted its holdings in IQVIA by 7.2% during the 1st quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock valued at $540,882,000 after purchasing an additional 143,533 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on IQV. JPMorgan Chase & Co. raised their price objective on shares of IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a report on Monday, August 5th. Barclays raised their price target on IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. Royal Bank of Canada initiated coverage on IQVIA in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price objective on the stock. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Friday. Finally, Robert W. Baird lifted their price target on IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a report on Friday, September 20th. Five analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus target price of $267.00.

IQVIA Trading Down 0.6 %

IQV opened at $234.79 on Friday. The firm has a 50 day simple moving average of $241.49 and a 200 day simple moving average of $233.52. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The company has a market cap of $42.80 billion, a price-to-earnings ratio of 32.08, a price-to-earnings-growth ratio of 2.25 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85.

IQVIA (NYSE:IQV) last issued its earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating the consensus estimate of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. During the same quarter in the previous year, the company posted $2.22 EPS. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.